Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)-Reference-Cited by-同舟云学术

Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)

Published:2015-09-15 Issue:18 Volume:58 Page:7173-7185
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Futatsugi Kentaro¹²,Kung Daniel W.¹²,Orr Suvi T. M.¹²,Cabral Shawn¹²,Hepworth David¹²,Aspnes Gary¹²,Bader Scott¹²,Bian Jianwei¹²,Boehm Markus¹²,Carpino Philip A.¹²,Coffey Steven B.¹²,Dowling Matthew S.¹²,Herr Michael¹²,Jiao Wenhua¹²,Lavergne Sophie Y.¹²,Li Qifang¹²,Clark Ronald W.¹²,Erion Derek M.¹²,Kou Kou¹²,Lee Kyuha¹²,Pabst Brandon A.¹²,Perez Sylvie M.¹²,Purkal Julie¹²,Jorgensen Csilla C.¹²,Goosen Theunis C.¹²,Gosset James R.¹²,Niosi Mark¹²,Pettersen John C.¹²,Pfefferkorn Jeffrey A.¹²,Ahn Kay¹²,Goodwin Bryan¹²

Affiliation:

1. Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States

2. Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01006

Reference62 articles.

1. Raised cholesterol: Situation and Trends.Global Health Observatory (GHO) Data;World Health Organization:Geneva, 2015; http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/.

2. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

3. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

4. Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

5. Common variants associated with plasma triglycerides and risk for coronary artery disease

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DGAT2 Plays a Crucial Role to Control ESRRAPROX1 Transcriptional Network to Maintain Hepatic Mitochondrial Sustainability;Diabetes & Metabolism Journal;2024-09-30

2. α-Synuclein acts as a cholesteryl-ester sensor on lipid droplets regulating organelle size and abundance;2024-06-20

3. Reorganization of innate immune cell lipid profiles by bioinspired meroterpenoids to limit inflammation;2024-05-28

4. Nuclear lipid droplets in Caco2 cells originate from nascent precursors and in situ at the nuclear envelope;Journal of Lipid Research;2024-05

5. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER;Cell Metabolism;2024-03